However, the general nature of the results presented here makes it likely that p38/MK2 inhibition also sensitizes AML cells to TS death, and might help to account for the substantial in vivo efficacy of the SM/p38i combination treatment (Lalaoui et al., 2016). The gene discussed is MAPK14; the disease is acute myeloid leukemia.